VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Failing to recognize this can result in lower productivity, higher company costs and turnover. Embracing a skills-based ...

Vertex (VERX – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Chris Quintero from ...

Hire Resolve’s client, an established media company ... Dataproc, and Vertex AI to transform raw data into actionable insights. We need someone with a deep understanding of data structures, adept ...

LONDON–(BUSINESS WIRE)–Today Northflank, the workload platform for developers, announced $22.3 million in new financing ...

Technology services and consulting firm Wipro Limited partnered with Google Cloud to introduce the ‘Google Gemini Experience ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

The Global Skills Academy (GSA), together with its private and strategic partners, are on a mission to support ten million youth and adults from around the world in building skills for improved ...